A pathophysiologic role for epidermal growth factor receptor in pemphigus acantholysis

Meryem Bektas, Puneet S. Jolly, Paula Berkowitz, Masayuki Amagai, David S. Rubenstein

研究成果: Article査読

47 被引用数 (Scopus)


The pemphigus family of autoimmune bullous disorders is characterized by autoantibody binding to desmoglein 1 and/or 3 (dsg1/dsg3). In this study we show that EGF receptor (EGFR) is activated following pemphigus vulgaris (PV) IgG treatment of primary human keratinocytes and that EGFR activation is downstream of p38 mitogen-activated protein kinase (p38). Inhibition of EGFR blocked PV IgG-triggered dsg3 endocytosis, keratin intermediate filament retraction, and loss of cell-cell adhesion in vitro. Significantly, inhibiting EGFR prevented PV IgG-induced blister formation in the passive transfer mouse model of pemphigus. These data demonstrate cross-talk between dsg3 and EGFR, that this cross-talk is regulated by p38, and that EGFR is a potential therapeutic target for pemphigus. Small-molecule inhibitors and monoclonal antibodies directed against EGFR are currently used to treat several types of solid tumors. This study provides the experimental rationale for investigating the use of EGFR inhibitors in pemphigus.

ジャーナルJournal of Biological Chemistry
出版ステータスPublished - 2013 3月 29

ASJC Scopus subject areas

  • 生化学
  • 分子生物学
  • 細胞生物学


「A pathophysiologic role for epidermal growth factor receptor in pemphigus acantholysis」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。